IJR News — today's news from every side

IJR News — today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Loading

Genius — OpenServe

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

OpenServe Drive OpenServe Inbox OpenServe Write OpenServe Studio OpenServe Projects OpenServe Focus OpenServe Mindmaps Teams OpenServe CRM Site Builder Whiteboard

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

News

Home
Popular
Elections

Genius — OpenServe

Experimental pancreatic cancer drug now available in Nebraska — Jul 23, 2026Daraxonrasib, an investigational KRAS-targeting drug, has shown the potential to more than double survival in stage IV pancreatic cancer compared with chemotherapy and is being offered through expanded access programs at Nebraska Medicine, with Ben Sasse publicly discussing his positive response. The FDA has accepted an NDA for daraxonrasib based on phase 3 trial results showing significant improvements in overall survival, progression-free survival, and response rate, signaling a possible breakthrough though not yet FDA approved.

0